Yue Li

Yue Li

Auto-generated profile, based on publicly available information

Yue Li

Academicians Workstation of Jilin Province, Changchun University of Chinese Medicine, Changchun, Jilin, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2023 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Open access
PDF file
YLYue Li
Yue Li
XYXia Yang
Xia Yang
JHJicheng Han
Jicheng Han
BBBing Bai
Bing Bai
YLYaru Li
Yaru Li
YZYilong Zhu
Yilong Zhu
Objectives: Inflammatory cytokine secretion and gut microbiota dysbiosis play crucial roles in ulcerative colitis. In this research, the protective effects of peimisine on colitis mice were investigated. Methods: The protective effects were evaluated by the disease activity index, colonic length, hematoxylin–eosin, and AB/PAS Staining. The protective mechanisms were analyzed by ELISA, Western-blot, immunohistochemistry staining, immunofluorescence staining, and 16S rRNA gene analysis. Key findings: The results showed that peimisine treatment could reduce the disease activity index, prevent colonic shortening, and alleviate colon tissue damage. Peimisine treatment also decreased the levels of MCP-1, IL-1β, IL-6, IFN-γ, TNF-α and affected macrophage polarization and Th17/Treg cell balance by downregulating the expression of jak1/2, p-jak1/2, stat1/3, and p-stat1/3. Moreover, peimisine treatment significantly increased the abundances of beneficial microbes (e.g. Ruminococcaceae UCG-014 and Lachnospiraceae_NK4A136_group) and decreased the abundances of harmful microbes (e.g. Bacteroides and Escherichia). Conclusions: Peimisine can ameliorate colitis by inhibiting Jak–Stat signaling pathway, reversing gut microbiota alterations, suppressing macrophage M1 polarization, maintaining the Th17/Treg cell balance, and reducing sustained inflammatory cytokines-related inflammatory injury.

10 February 2023 in Journal of Functional Foods
Verified
Journal Article
Open access
ZXZhiru Xiu
Zhiru Xiu
YZYilong Zhu
Yilong Zhu
SLShanzhi Li
Shanzhi Li
YLYaru Li
Yaru Li
XYXia Yang
Xia Yang
XLXiao Li
Xiao Li

1 January 2025 in Human Mutation
Verified
Journal Article
Open access
YWYining Wan
Yining Wan
JLJinqiu Li
Jinqiu Li
YGYingyuan Guo
Yingyuan Guo
FGFang Guo
Fang Guo
YZYing Zhao
Ying Zhao
XLXiao Li
Xiao Li
Purpose: The study was aimed at identifying the pathogenic gene responsible for X‐linked nonsyndromic hearing loss (NSHL) in a five‐generation Chinese family and at elucidating the gene’s function both in vivo using a zebrafish model and in vitro using PRPS1 knockdown HEI‐OC1 cells.Methods: Exome sequencing (ES) and Sanger sequencing were used to identify the pathogenic variants. A transgenic zebrafish model overexpressing the novel PRPS1 variant (c.494G>A: p.Cys165Tyr) was constructed, and PRPS1 was knocked down in HEI‐OC1 cells using siRNA to explore the underlying mechanisms. Hair cell development and behavior were assessed in zebrafish, and mitochondrial function and cell viability were analyzed in HEI‐OC1 cells.Results: A novel missense variant (c.494G>A: p.Cys165Tyr) in the PRPS1 gene was identified as the pathogenic variant causing progressive X‐linked deafness‐1 (DFNX1). The variant led to hair cell death in zebrafish, with disrupted swimming behavior. In HEI‐OC1 cells, PRPS1 knockdown resulted in downregulation of the nicotinamide adenine dinucleotide (NAD+)/sirtuin 3 (SIRT3)/superoxide dismutase 2 (SOD2) pathway, increased reactive oxygen species (ROS) accumulation, mitochondrial dysfunction, and apoptosis, which were partially rescued by pretreatment with nicotinamide mononucleotide (NMN), a precursor of NAD+.Conclusion: The study reports a novel PRPS1 variant contributing to the variant spectrum of PRPS1 and highlights the role of PRPS1 deficiency in increasing oxidative stress‐induced hair cell apoptosis via the NAD+/SIRT3/SOD2 pathway. These findings provide new insights into the molecular mechanisms of PRPS1‐related hearing loss and potential therapeutic targets.